- Trials with a EudraCT protocol (44,347)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,347 result(s) found.
Displaying page 1,186 of 2,218.
EudraCT Number: 2011-001952-12 | Sponsor Protocol Number: CAFQ056B2279 | Start Date*: 2011-11-03 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label study to evaluate the long-term safety, tolerability and efficacy of AFQ056 in adult patients with Fragile X Syndrome | |||||||||||||
Medical condition: Fragile X Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) GB (Prematurely Ended) DK (Prematurely Ended) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000966-40 | Sponsor Protocol Number: EC-FV-07 | Start Date*: 2012-07-04 | ||||||||||||||||
Sponsor Name:Endocyte, Inc. | ||||||||||||||||||
Full Title: A Randomized, Open-Label Phase 2 Study of EC145 Single-agent and the Combination of EC145 plus Docetaxel Versus Docetaxel Alone in Participants with Folate-Receptor Positive [FR(++)] Second Line NSCLC | ||||||||||||||||||
Medical condition: Second line FR(++) non-small cell lung cancer (adenocarcinoma, squamous, adenosquamous, or adenocarcinoma with other NSCLC variants of the lung) (Stage IIIB or IV). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) CZ (Completed) ES (Completed) GB (Completed) BG (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-001251-40 | Sponsor Protocol Number: MEA115588 | Start Date*: 2012-10-16 |
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
Full Title: MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncon... | ||
Medical condition: Subjects with severe, refractory, uncontrolled asthma with elevated blood eosinphils | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed) Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2011-003810-18 | Sponsor Protocol Number: H9X-MC-GBDE | Start Date*: 2012-07-11 | |||||||||||
Sponsor Name:Eli Lilly & Company | |||||||||||||
Full Title: A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Once-Daily Liraglutide in Patients with Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRati... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) DE (Completed) PL (Completed) ES (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001616-33 | Sponsor Protocol Number: MEM-MD-91 | Start Date*: 2012-11-14 | |||||||||||||||||||||
Sponsor Name:Forest Research Institute, Inc. | |||||||||||||||||||||||
Full Title: An Open-Label Study Of The Safety And Tolerability Of Memantine In Pediatric Patients With Autism, Asperger’s Disorder, Or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) | |||||||||||||||||||||||
Medical condition: Autism or Asperger’s Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) IS (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004023-20 | Sponsor Protocol Number: CLDE225X2116 | Start Date*: 2013-06-21 | |||||||||||
Sponsor Name:Novartis Farmacéutica S.A. | |||||||||||||
Full Title: A Phase Ib/II, open-label, multi-center, dose-finding study to assess the safety and efficacy of the oral combination of LDE225 and INC424 (Ruxolitinib) in patients with myelofibrosis | |||||||||||||
Medical condition: myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (Prematurely Ended) IE (Prematurely Ended) IT (Completed) DE (Completed) NL (Prematurely Ended) FR (Prematurely Ended) DK (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002338-35 | Sponsor Protocol Number: 144 | Start Date*: 2013-05-06 | |||||||||||
Sponsor Name:Biosense Webster, Inc. | |||||||||||||
Full Title: ATrial FibrillaTion ProgrESsion Trial (ATTEST Trial) | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) ES (Completed) IE (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000691-15 | Sponsor Protocol Number: B1871040 | Start Date*: 2013-07-08 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008 | |||||||||||||
Medical condition: Chronic Myeloid Leukemia (CML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) HU (Completed) LT (Prematurely Ended) LV (Completed) NL (Completed) FI (Completed) ES (Completed) GB (Completed) FR (Completed) BE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003132-79 | Sponsor Protocol Number: EFC12405 | Start Date*: 2014-01-21 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: A randomized, 30-week, active-controlled, open label, 2-treatment arm, parallel-group, multicenter study comparing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combinati... | |||||||||||||
Medical condition: Type II Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) SE (Completed) LT (Completed) CZ (Completed) NL (Completed) ES (Completed) HU (Completed) SK (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000055-41 | Sponsor Protocol Number: CV185-220 | Start Date*: 2013-08-09 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) | |||||||||||||
Medical condition: Patients with Non-Valvular Atrial Fibrillation with at least one risk factor for stroke and indicated for oral anticoagulant. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) ES (Completed) DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003879-37 | Sponsor Protocol Number: 42160443PAI3002 | Start Date*: 2015-07-17 | ||||||||||||||||
Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||
Full Title: Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects with Signs and Symptoms of Osteo... | ||||||||||||||||||
Medical condition: Osteoarthritis of the Hip or Knee | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005215-33 | Sponsor Protocol Number: CLJN452A2202 | Start Date*: 2016-06-17 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo controlled, 3- part, adaptive design, multicenter study to assess safety, tolerability and efficacy of tropifexor (LJN452) in patients with non-alcoholic steatoh... | |||||||||||||
Medical condition: Non-alcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) IT (Completed) DE (Completed) NL (Completed) BE (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001233-27 | Sponsor Protocol Number: PI2016_843_0008 | Start Date*: 2016-11-03 | |||||||||||
Sponsor Name:CHU Amiens Picardie | |||||||||||||
Full Title: Efficacity and safety of metformin extended release (XR) in diabetic patients with CKD in stages 1 to 3 (METXR/CKD) | |||||||||||||
Medical condition: type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004247-37 | Sponsor Protocol Number: 38RC16.046 | Start Date*: 2017-05-04 |
Sponsor Name:University Hospital Grenoble | ||
Full Title: NA | ||
Medical condition: coagulopathy secondary to traumatic hemorrhagic shock | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002470-20 | Sponsor Protocol Number: SANNI-project:01 | Start Date*: 2017-04-11 |
Sponsor Name:Skåne University Hospital | ||
Full Title: Fentanyl and Clonidine for analgesia during hypothermia in term asphyxiated infants – a prospective pharmacokinetic/ pharmacodynamic/ pharmacogenetic observational study. Cohort 1 in The SANNI proj... | ||
Medical condition: Infants with induced hypothermic treatment after perinatal asphyxia | ||
Disease: | ||
Population Age: Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004405-64 | Sponsor Protocol Number: MT-2-03 | Start Date*: 2019-03-07 | |||||||||||
Sponsor Name:Minoryx Therapeutics BE, SA | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological, and Clinical Markers in Patients with Friedreich’s Ataxia | |||||||||||||
Medical condition: Friedreich’s Ataxia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005319-33 | Sponsor Protocol Number: BuS2020 | Start Date*: 2021-09-22 | |||||||||||
Sponsor Name:Fundación Cínic per a la Reserca Biomèdica | |||||||||||||
Full Title: EFFICACY AND SAFETY OF THE INTRATRACHEAL ADMINISTRATION OF BUDESONIDE WITH SURFACTANT IN VERY PRETERM INFANTS TO PREVENT BRONCHOPULMONARY DYSPLASIA: RANDOMIZED CLINICAL TRIAL | |||||||||||||
Medical condition: Bronchopulmonary dysplasia of prematurity | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005709-50 | Sponsor Protocol Number: 1122005 | Start Date*: 2006-05-05 |
Sponsor Name:Cardiology, University of Frankfurt | ||
Full Title: Extracorporal shock wave therapy for induction of therapeutic neovascularization and homing of bone marrow progenitor cells in patients with chronic ischemic heart disease | ||
Medical condition: Patients with ischemic coronary artery disease (congestive heart failure) and s/p anterior myocardial infarction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-001778-21 | Sponsor Protocol Number: A4001028 | Start Date*: 2005-02-02 |
Sponsor Name:PFIZER LTD | ||
Full Title: A multicentre, randomised, double-blind, placebo-controlled trial of a novel CCR5 antagonist, UK-427,857 in combination with optimised background therapy versus optimised background therapy alone f... | ||
Medical condition: UK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in indivuduals HIV-1 positive. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-005276-16 | Sponsor Protocol Number: ET743-OVA-301 | Start Date*: 2005-10-27 | |||||||||||
Sponsor Name:Pharma Mar S.A. | |||||||||||||
Full Title: An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer. | |||||||||||||
Medical condition: Advanced relapsed ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
